董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Arkowitz | 男 | Director | 64 | 6.42万美元 | 未持股 | 2025-11-20 |
| Gary Sender | 男 | Director | 63 | 11.76万美元 | 未持股 | 2025-11-20 |
| Martin B. Brenner | 男 | Chief Executive Officer,Chief Scientific Officer and Director | 54 | 150.99万美元 | 未持股 | 2025-11-20 |
| Alexandra Kropotova | 女 | Director | 52 | 10.03万美元 | 未持股 | 2025-11-20 |
| Evert Schimmelpennink | 男 | Director | 53 | 9.43万美元 | 未持股 | 2025-11-20 |
| William D. Clark | 男 | Chairperson of the Board | 57 | 13.43万美元 | 未持股 | 2025-11-20 |
| António Parada | 男 | Director | 57 | 5.82万美元 | 未持股 | 2025-11-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin B. Brenner | 男 | Chief Executive Officer,Chief Scientific Officer and Director | 54 | 150.99万美元 | 未持股 | 2025-11-20 |
| Felipe Duran | 男 | Chief Financial Officer | 46 | 77.01万美元 | 未持股 | 2025-11-20 |
| Marc Banjak | 男 | Chief Legal Counsel | 48 | 71.29万美元 | 未持股 | 2025-11-20 |
董事简历
中英对照 | 中文 | 英文- David Arkowitz
-
David Arkowitz，2014年2月起担任董事会成员。2013年起在生物技术公司Visterra, Inc.担任首席运营官和财务总监。此前，2011年6月-2013年9月，在 Mascoma Corporation（该公司被一家生物转化公司- Lallemand, Inc.收购）担任财务总监和总经理。2007年4月-2011年5月，在一家专业医药公司-AMAG Pharmaceuticals，担任执行副总裁、财务总监和首席商务官。此前，他曾担任Idenix Pharmaceuticals, Inc.（被生物医药公司Merck & Co.，收购）的财务总监和司库。在职业生涯的早期，他曾在 Merck & Co. 工作了超过13年，包括U.S. Human Health副总裁和总会计师，以及全球研发部总会计师。2007-2009，在Aegerion Pharmaceuticals, Inc.，以及2005-2009在 ImpactRx Inc. 董事会任职。他持有Brandeis 大学的数学学士学位和Columbia 大学商学院的财务专业工商管理硕士学位。
David Arkowitz has been a member of our Board of Directors since January 2014. Since May 2018 Mr. Arkowitz has served as the Chief Financial Officer and Treasurer of Flexion Therapeutics, Inc., a biotechnology company. Prior to that, Mr. Arkowitz served as Chief Operating Officer and Chief Financial Officer of Visterra, Inc., which was acquired by Otsuka Pharmaceutical Co., Ltd., a biotechnology company, from September 2013 to May 2018. Prior to joining Visterra, he served as Chief Financial Officer and General Manager at Mascoma Corporation, which was acquired by Lallemand, Inc., a bioconversion company, from 2011 to 2013. From 2007 to 2011 Mr. Arkowitz was Executive Vice President, Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a specialty pharmaceutical company. Prior to his tenure at AMAG, he served as Chief Financial Officer and Treasurer of Idenix Pharmaceuticals, Inc., which was acquired by Merck & Co., a biopharmaceutical company. Earlier in his career, he spent more than thirteen years at Merck & Co. including as Vice President and Controller of the U.S. Human Health division and as Controller of the Global Research and Development division. Mr. Arkowitz currently serves on the board of directors of Proteostasis Therapeutics, Inc., a publicly traded biotechnology company, and previously served on the board of directors of Aegerion Pharmaceuticals, Inc., also a publicly traded biotechnology company. Mr. Arkowitz has a BA in Mathematics from Brandeis University and an MBA in Finance from Columbia University Business School. - David Arkowitz，2014年2月起担任董事会成员。2013年起在生物技术公司Visterra, Inc.担任首席运营官和财务总监。此前，2011年6月-2013年9月，在 Mascoma Corporation（该公司被一家生物转化公司- Lallemand, Inc.收购）担任财务总监和总经理。2007年4月-2011年5月，在一家专业医药公司-AMAG Pharmaceuticals，担任执行副总裁、财务总监和首席商务官。此前，他曾担任Idenix Pharmaceuticals, Inc.（被生物医药公司Merck & Co.，收购）的财务总监和司库。在职业生涯的早期，他曾在 Merck & Co. 工作了超过13年，包括U.S. Human Health副总裁和总会计师，以及全球研发部总会计师。2007-2009，在Aegerion Pharmaceuticals, Inc.，以及2005-2009在 ImpactRx Inc. 董事会任职。他持有Brandeis 大学的数学学士学位和Columbia 大学商学院的财务专业工商管理硕士学位。
- David Arkowitz has been a member of our Board of Directors since January 2014. Since May 2018 Mr. Arkowitz has served as the Chief Financial Officer and Treasurer of Flexion Therapeutics, Inc., a biotechnology company. Prior to that, Mr. Arkowitz served as Chief Operating Officer and Chief Financial Officer of Visterra, Inc., which was acquired by Otsuka Pharmaceutical Co., Ltd., a biotechnology company, from September 2013 to May 2018. Prior to joining Visterra, he served as Chief Financial Officer and General Manager at Mascoma Corporation, which was acquired by Lallemand, Inc., a bioconversion company, from 2011 to 2013. From 2007 to 2011 Mr. Arkowitz was Executive Vice President, Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a specialty pharmaceutical company. Prior to his tenure at AMAG, he served as Chief Financial Officer and Treasurer of Idenix Pharmaceuticals, Inc., which was acquired by Merck & Co., a biopharmaceutical company. Earlier in his career, he spent more than thirteen years at Merck & Co. including as Vice President and Controller of the U.S. Human Health division and as Controller of the Global Research and Development division. Mr. Arkowitz currently serves on the board of directors of Proteostasis Therapeutics, Inc., a publicly traded biotechnology company, and previously served on the board of directors of Aegerion Pharmaceuticals, Inc., also a publicly traded biotechnology company. Mr. Arkowitz has a BA in Mathematics from Brandeis University and an MBA in Finance from Columbia University Business School.
- Gary Sender
-
Gary Sender于2020年10月被任命为董事会成员，目前担任董事会审计委员会主席和薪酬委员会成员。Sender先生是一位高级执行官和董事会成员，在大型，跨国制药和早期生物技术公司拥有超过25年的财务领导经验。他曾担任Nabriva Therapeutics plc（Nasdaq:NBRV）的首席财务官，该公司是一家商业阶段的上市生物制药公司，自2016年5月起从事创新抗感染药物的商业化和开发，以治疗严重感染。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任Synergy PharmaceuticalsInc.执行Vice President兼首席财务官。此前，从2009年8月到2015年6月，森德还担任过Shire plc的财务高级副总裁，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生从2004年8月到2009年7月担任再生医学公司Tengion，Inc.的首席财务官。Sender先生还在默克公司（Merck&Co.）担任了15年多的领导职务。Inc.，一家制药公司。Sender先生目前在Harmony Biosciences（NASDAQ:HRMY）的董事会任职，并担任其审计委员会主席，并且是其薪酬委员会的成员，也在Schr&246；Dinger，Inc（NASDAQ:SDGR）的董事会任职，并担任其审计和薪酬委员会主席。他持有Boston University的财务和信息系统学士学位，以及Carnegie Mellon University的工商管理硕士学位。
Gary Sender,was appointed as a member of Ibio, Inc. Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee of the Board of Directors and as a member of Ibio, Inc. Compensation Committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender currently serves on the board of directors of Schrodinger, Inc. and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences and is the chair of their audit committee and is a member on their compensation committee. Mr. Sender serves on the board of Gennao Bio, a privately held biotechnology firm. He is the chair of both the audit and compensation committees of Gennao. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University. - Gary Sender于2020年10月被任命为董事会成员，目前担任董事会审计委员会主席和薪酬委员会成员。Sender先生是一位高级执行官和董事会成员，在大型，跨国制药和早期生物技术公司拥有超过25年的财务领导经验。他曾担任Nabriva Therapeutics plc（Nasdaq:NBRV）的首席财务官，该公司是一家商业阶段的上市生物制药公司，自2016年5月起从事创新抗感染药物的商业化和开发，以治疗严重感染。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任Synergy PharmaceuticalsInc.执行Vice President兼首席财务官。此前，从2009年8月到2015年6月，森德还担任过Shire plc的财务高级副总裁，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生从2004年8月到2009年7月担任再生医学公司Tengion，Inc.的首席财务官。Sender先生还在默克公司（Merck&Co.）担任了15年多的领导职务。Inc.，一家制药公司。Sender先生目前在Harmony Biosciences（NASDAQ:HRMY）的董事会任职，并担任其审计委员会主席，并且是其薪酬委员会的成员，也在Schr&246；Dinger，Inc（NASDAQ:SDGR）的董事会任职，并担任其审计和薪酬委员会主席。他持有Boston University的财务和信息系统学士学位，以及Carnegie Mellon University的工商管理硕士学位。
- Gary Sender,was appointed as a member of Ibio, Inc. Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee of the Board of Directors and as a member of Ibio, Inc. Compensation Committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender currently serves on the board of directors of Schrodinger, Inc. and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences and is the chair of their audit committee and is a member on their compensation committee. Mr. Sender serves on the board of Gennao Bio, a privately held biotechnology firm. He is the chair of both the audit and compensation committees of Gennao. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University.
- Martin B. Brenner
-
MartinB.Brenner自2019年3月起担任我们的高级副总裁，首席科学官。2017年至2018年，Brenner博士担任生物技术公司Recursion Pharmaceuticals，Inc.的首席科学官。2016年至2017年，Brenner博士担任生物技术公司StokeTherapeutics，Inc.的Vice President兼研发主管。从2013年到2016年，Brenner博士担任默克制药公司默克研究实验室（Merck Research Laboratories）糖尿病与NASH执行董事兼糖尿病与NASH早期发现部门主席。2012年至2013年，Brenner博士担任制药公司AstraZeneca PLC CVMD的高级董事、生物科学主管。从2009年到2012年，Brenner博士担任制药公司辉瑞公司糖尿病预防和缓解组的副研究员。从2003年到2009年，Brenner博士担任礼来公司（一家制药公司）糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威的汉诺威兽医学院（Veterinary School of Hannover）药理学博士学位和德国慕尼黑的路德维希-马克西米利安大学（Ludwig-Maximilians-University）兽医学院的DVM。
Martin B. Brenner,has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany. - MartinB.Brenner自2019年3月起担任我们的高级副总裁，首席科学官。2017年至2018年，Brenner博士担任生物技术公司Recursion Pharmaceuticals，Inc.的首席科学官。2016年至2017年，Brenner博士担任生物技术公司StokeTherapeutics，Inc.的Vice President兼研发主管。从2013年到2016年，Brenner博士担任默克制药公司默克研究实验室（Merck Research Laboratories）糖尿病与NASH执行董事兼糖尿病与NASH早期发现部门主席。2012年至2013年，Brenner博士担任制药公司AstraZeneca PLC CVMD的高级董事、生物科学主管。从2009年到2012年，Brenner博士担任制药公司辉瑞公司糖尿病预防和缓解组的副研究员。从2003年到2009年，Brenner博士担任礼来公司（一家制药公司）糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威的汉诺威兽医学院（Veterinary School of Hannover）药理学博士学位和德国慕尼黑的路德维希-马克西米利安大学（Ludwig-Maximilians-University）兽医学院的DVM。
- Martin B. Brenner,has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.
- Alexandra Kropotova
-
Alexandra Kropotova于2020年10月被任命为董事会成员，目前担任董事会新成立的科学和技术委员会成员。Kropotova博士是一位生物制药执行官，在全球临床开发，转化医学和医疗事务的所有阶段都拥有专业知识。自2016年以来，她一直担任Teva Pharmaceuticals Tase:Teva的Vice President，负责全球专业研发，呼吸和炎症治疗领域，领导全球临床开发计划的设计和执行，其中大多数是肺部，慢性炎症或自身免疫适应症的生物候选药物。在加入Teva之前，Kropotova博士曾于2007年至2016年在赛诺菲（EPA:SAN）担任多个职位，包括北美医疗事务战略与战略规划主管Vice President；Vice President助理，随后担任全球研发免疫炎症Vice President；呼吸、过敏和抗感染高级医疗总监。在加入赛诺菲之前，她从2002年到2007年在辉瑞公司（纽约证券交易所代码:PFE）担任多个职位，最近的职位是担任全球临床呼吸和止痛药总监兼主管。Kropotova博士在俄亥俄州雅典的俄亥俄大学商学院（Ohio University Graduate School of Business）获得工商管理硕士学位，并在俄罗斯符拉迪沃斯托克的符拉迪沃斯托克州立医科大学（Vladivostok State Medical University）获得内科医学学位。
Alexandra Kropotova,is Executive Vice President & Chief Medical Officer as of June, 2022, leading the strategy, direction, and execution of the company's clinical development for the entire portfolio. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Prior to joining SAB Biotherapeutics, as a Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals from April 2016 to June 2022, Alexandra led innovative drug development focused on delivering a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products. Prior to Teva, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She also served in various roles at Pfizer Inc., most recently as Director & Head of Global Clinical Respiratory and Analgesics. She continues to serve on the Board of Directors at iBio, a global leader in plant-based biologics manufacturing and development of novel biopharmaceuticals. Dr. Kropotova received her MBA from Ohio University Graduate School of Business, Athens, Ohio; and her M.D. in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia. - Alexandra Kropotova于2020年10月被任命为董事会成员，目前担任董事会新成立的科学和技术委员会成员。Kropotova博士是一位生物制药执行官，在全球临床开发，转化医学和医疗事务的所有阶段都拥有专业知识。自2016年以来，她一直担任Teva Pharmaceuticals Tase:Teva的Vice President，负责全球专业研发，呼吸和炎症治疗领域，领导全球临床开发计划的设计和执行，其中大多数是肺部，慢性炎症或自身免疫适应症的生物候选药物。在加入Teva之前，Kropotova博士曾于2007年至2016年在赛诺菲（EPA:SAN）担任多个职位，包括北美医疗事务战略与战略规划主管Vice President；Vice President助理，随后担任全球研发免疫炎症Vice President；呼吸、过敏和抗感染高级医疗总监。在加入赛诺菲之前，她从2002年到2007年在辉瑞公司（纽约证券交易所代码:PFE）担任多个职位，最近的职位是担任全球临床呼吸和止痛药总监兼主管。Kropotova博士在俄亥俄州雅典的俄亥俄大学商学院（Ohio University Graduate School of Business）获得工商管理硕士学位，并在俄罗斯符拉迪沃斯托克的符拉迪沃斯托克州立医科大学（Vladivostok State Medical University）获得内科医学学位。
- Alexandra Kropotova,is Executive Vice President & Chief Medical Officer as of June, 2022, leading the strategy, direction, and execution of the company's clinical development for the entire portfolio. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Prior to joining SAB Biotherapeutics, as a Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals from April 2016 to June 2022, Alexandra led innovative drug development focused on delivering a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products. Prior to Teva, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She also served in various roles at Pfizer Inc., most recently as Director & Head of Global Clinical Respiratory and Analgesics. She continues to serve on the Board of Directors at iBio, a global leader in plant-based biologics manufacturing and development of novel biopharmaceuticals. Dr. Kropotova received her MBA from Ohio University Graduate School of Business, Athens, Ohio; and her M.D. in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.
- Evert Schimmelpennink
-
Evert Schimmelpennink于2021年6月被任命为董事会成员，目前担任提名和公司治理委员会主席以及科学技术委员会成员。Schimmelpennink先生拥有近25年的生物技术和制药经验，并在成功建立和扩展公共和私人生物制药公司，围绕迷人的战略获得资金以及创造患者和股东价值方面拥有良好的记录。Schimmelpennink先生目前担任Lenz Therapeutics，Inc.的首席执行官兼总裁，自2021年3月4日起担任该职位。此前，从2017年8月至2020年10月，他担任公开上市的Pfenex Inc.的首席执行官，他领导该公司实现了扭亏为盈，并获得了FDA的首次批准，从而在2020年末被Ligand Pharmaceuticals Inc.收购。从2019年11月13日至出售，Schimmelpennink先生还担任Pfenex Inc.的代理首席财务官兼首席会计官从2015年10月至2017年7月，Schimmelpennink先生担任私人控股的Alvotech的首席执行官，在那里他领导公司度过了关键的增长阶段，并在单克隆抗体投资组合中整合了研发，制造和商业能力。在此之前，他在辉瑞公司和好比拉医疗保健公司的全球特种注射剂业务以及Synthon BV担任高级职位。Schimmelpennink先生获得了理学硕士学位。在荷兰瓦格宁根大学获得生物过程工程学位，并在阿纳姆商学院获得商业学位。
Evert Schimmelpennink,was appointed as a member of Ibio, Inc. Board of Directors in April 2019. He also currently serves on the Nominating and Corporate Governance Committee and served as a member of the Science and Technology Committee until its disbandment.Mr. Schimmelpennink currently serves as the Chief Executive Officer (CEO) and President of publicly listed LENZ Therapeutics, Inc. a position he has held since March 4, 2021. Previously, from August 2017 to October 2020 he was the CEO of publicly listed Pfenex Inc., which he led through a turnaround and its first FDA approval resulting in an acquisition by Ligand Pharmaceuticals Inc. in late 2020. From November 13, 2019 until its sale, Mr. Schimmelpennink also served as the acting Principal Financial Officer and Principal Accounting Officer of Pfenex Inc. From October 2015 to July 2017, Mr. Schimmelpennink was CEO of then privately held Alvotech, where he led the company through a critical growth phase, and aligned R&D, manufacturing and commercial capabilities across a portfolio of monoclonal antibodies. Prior to that, he held senior positions at Pfizer Inc. and Hospira, Inc. within their global specialty injectables businesses, as well as Synthon BV. In addition to serving on the board of directors of LENZ Therapeutics, Mr. Schimmelpennink serves on the board of directors of Pipeline Therapeutics, Inc. Mr. Schimmelpennink earned a M.Sc. in bioprocess engineering from the University of Wageningen in the Netherlands and a Business Degree from the Arnhem Business School. - Evert Schimmelpennink于2021年6月被任命为董事会成员，目前担任提名和公司治理委员会主席以及科学技术委员会成员。Schimmelpennink先生拥有近25年的生物技术和制药经验，并在成功建立和扩展公共和私人生物制药公司，围绕迷人的战略获得资金以及创造患者和股东价值方面拥有良好的记录。Schimmelpennink先生目前担任Lenz Therapeutics，Inc.的首席执行官兼总裁，自2021年3月4日起担任该职位。此前，从2017年8月至2020年10月，他担任公开上市的Pfenex Inc.的首席执行官，他领导该公司实现了扭亏为盈，并获得了FDA的首次批准，从而在2020年末被Ligand Pharmaceuticals Inc.收购。从2019年11月13日至出售，Schimmelpennink先生还担任Pfenex Inc.的代理首席财务官兼首席会计官从2015年10月至2017年7月，Schimmelpennink先生担任私人控股的Alvotech的首席执行官，在那里他领导公司度过了关键的增长阶段，并在单克隆抗体投资组合中整合了研发，制造和商业能力。在此之前，他在辉瑞公司和好比拉医疗保健公司的全球特种注射剂业务以及Synthon BV担任高级职位。Schimmelpennink先生获得了理学硕士学位。在荷兰瓦格宁根大学获得生物过程工程学位，并在阿纳姆商学院获得商业学位。
- Evert Schimmelpennink,was appointed as a member of Ibio, Inc. Board of Directors in April 2019. He also currently serves on the Nominating and Corporate Governance Committee and served as a member of the Science and Technology Committee until its disbandment.Mr. Schimmelpennink currently serves as the Chief Executive Officer (CEO) and President of publicly listed LENZ Therapeutics, Inc. a position he has held since March 4, 2021. Previously, from August 2017 to October 2020 he was the CEO of publicly listed Pfenex Inc., which he led through a turnaround and its first FDA approval resulting in an acquisition by Ligand Pharmaceuticals Inc. in late 2020. From November 13, 2019 until its sale, Mr. Schimmelpennink also served as the acting Principal Financial Officer and Principal Accounting Officer of Pfenex Inc. From October 2015 to July 2017, Mr. Schimmelpennink was CEO of then privately held Alvotech, where he led the company through a critical growth phase, and aligned R&D, manufacturing and commercial capabilities across a portfolio of monoclonal antibodies. Prior to that, he held senior positions at Pfizer Inc. and Hospira, Inc. within their global specialty injectables businesses, as well as Synthon BV. In addition to serving on the board of directors of LENZ Therapeutics, Mr. Schimmelpennink serves on the board of directors of Pipeline Therapeutics, Inc. Mr. Schimmelpennink earned a M.Sc. in bioprocess engineering from the University of Wageningen in the Netherlands and a Business Degree from the Arnhem Business School.
- William D. Clark
-
William D. Clark于2021年8月被任命为我们的董事会成员，目前担任审计委员会，提名和公司治理委员会成员。Clark先生拥有超过30年的生物技术和制药经验，专注于业务开发、商业化、战略规划和综合管理。2011年以来，他担任纳斯达克上市的生物制药公司Genocea Biosciences, Inc.“；Genocea”；的总裁兼首席执行官。在这个职位上，除了其他成就外，他成功地执行了Genocea从传染病到免疫肿瘤学的战略转型。加入Genocea之前，他曾担任Vanda Pharmaceuticals Inc.“；Vanda”；的首席商务官，这是一家他于2004年联合创立的公司。在那里，他在完成公司2006年在纳斯达克的首次公开发行和2009年与Novartis Pharma AG的授权交易中发挥了核心作用，Vanda从该交易中获得了2亿美元的预付款，以及总计2.65亿美元的未来里程碑付款。此前，他曾担任Care Capital公司（投资生物制药公司的风险投资公司）的负责人。职业生涯早期，他曾任职SmithKline Beecham Corporation（现为GlaxoSmithKline plc的一部分）10年，担任多种业务开发职务。Clark先生拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位和哈佛大学的文学学士学位。
William D. Clark,was appointed as a member of Ibio, Inc. Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee and Nominating and Corporate Governance Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Currently, Mr. Clark serves as President and CEO of Vibrant Biomedicines, Inc. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). In that role, among other accomplishments, he executed Genocea's successful strategic pivot from infectious disease to immuno-oncology. Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co-founded in 2004. There, he played central roles in completing the company's 2006 initial public offering and its 2009 out-licensing deal with Novartis Pharma AG, from which Vanda received an upfront payment of $200 million, plus contingent additional future milestone payments totaling up to $265 million. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of business development roles. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University. - William D. Clark于2021年8月被任命为我们的董事会成员，目前担任审计委员会，提名和公司治理委员会成员。Clark先生拥有超过30年的生物技术和制药经验，专注于业务开发、商业化、战略规划和综合管理。2011年以来，他担任纳斯达克上市的生物制药公司Genocea Biosciences, Inc.“；Genocea”；的总裁兼首席执行官。在这个职位上，除了其他成就外，他成功地执行了Genocea从传染病到免疫肿瘤学的战略转型。加入Genocea之前，他曾担任Vanda Pharmaceuticals Inc.“；Vanda”；的首席商务官，这是一家他于2004年联合创立的公司。在那里，他在完成公司2006年在纳斯达克的首次公开发行和2009年与Novartis Pharma AG的授权交易中发挥了核心作用，Vanda从该交易中获得了2亿美元的预付款，以及总计2.65亿美元的未来里程碑付款。此前，他曾担任Care Capital公司（投资生物制药公司的风险投资公司）的负责人。职业生涯早期，他曾任职SmithKline Beecham Corporation（现为GlaxoSmithKline plc的一部分）10年，担任多种业务开发职务。Clark先生拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位和哈佛大学的文学学士学位。
- William D. Clark,was appointed as a member of Ibio, Inc. Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee and Nominating and Corporate Governance Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Currently, Mr. Clark serves as President and CEO of Vibrant Biomedicines, Inc. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). In that role, among other accomplishments, he executed Genocea's successful strategic pivot from infectious disease to immuno-oncology. Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co-founded in 2004. There, he played central roles in completing the company's 2006 initial public offering and its 2009 out-licensing deal with Novartis Pharma AG, from which Vanda received an upfront payment of $200 million, plus contingent additional future milestone payments totaling up to $265 million. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of business development roles. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University.
- António Parada
-
Ant ó nio Parada于2024年11月被任命为iBio，Inc.董事会成员，目前担任提名和公司治理委员会成员。他目前是Fairjney Biologics的创始人兼首席执行官，该公司是一家私营公司，也是一家领先的抗体发现合同研究组织，为全球250多个客户提供支持，自2012年5月创立该公司以来，他一直担任这一职务。2024年6月，管理着约1500亿美元资产的全球私人市场最大公司之一Partners Group收购了FairJney的多数股权。在加入Fairjney之前，Parada先生曾于2002年至2013年担任葡萄牙Porta的Instituto de Biologia Molecular e Celular（IBMC）总经理。从2011年2月至2012年5月，Parada先生担任IPO Porto –葡萄牙波尔图肿瘤医院临床试验部门的经理。从2008年6月到2012年3月，Parada先生是Ablynx’（赛诺菲 S.A.的子公司）位于葡萄牙Portal的“噬菌体显示卓越中心”的现场经理。2002年6月，帕拉达先生创立了咨询公司BioCodex Group，并担任首席执行官直到2008年12月，该公司的营业额约为1000万欧元。Parada先生于2014年5月至2017年5月期间担任Centro de Diagn ó stico y Estudios Metab ó licos Avanzados de Cantabria（CDEMAC）的董事会成员，现任EMBLEM监事会主席，自2011年1月起担任该职务。帕拉达先生有15篇关于药理学的同行复刊jnals和其他几篇关于植物学、管理、营销和安全的出版物，并持有葡萄牙波尔图市的功绩勋章和葡萄牙马托西尼奥斯市的事业奖。Parada先生毕业于葡萄牙波尔图大学，拥有葡萄牙天主教大学MBA学位。
António Parada was appointed as a member of iBio, Inc. Board of Directors in November 2024 and currently serves as a member of the Nominating and Corporate Governance Committee. He is currently the Founder and CEO of Fairjney Biologics, a privately held company and a leading antibody discovery contract research organization supporting more than 250 clients across the globe, a role he has held since founding the company in May 2012. In June 2024, the Partners Group, one of the largest firms in the global private markets indtry with approximately $150 billion in assets under management, acquired a majority ownership in FairJney. Prior to Fairjney, Mr. Parada was the General Manager of Instituto de Biologia Molecular e Celular (IBMC), in Porta, Portugal, from 2002 until 2013. From February 2011 until May 2012, Mr. Parada was the Manager of the Clinical Trial Unit of IPO Porto – Cancer Hospital in Porto, Portugal. From June 2008 to March 2012, Mr. Parada was the Site Manager of Ablynx' (a subsidiary of Sanofi S.A.) "Centre of Excellence in Phage Display" located in Portal, Portugal. In June 2002, Mr. Parada founded the BioCodex Group, a consulting firm, and was the CEO until December 2008, which firm had a turnover of approximately 10 million Euros. Mr. Parada was a Board Member of Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 until May 2017 and is currently the Chairman of the Supervisory Board of EMBLEM, a position he has held since January 2011. Mr. Parada has 15 publications in peer revied jnals on pharmacology and several others in botany, management, marketing and security and holds the medal of Merit of the city of Porto, Portugal and career award of the city of Matosinhos, Portugal. Mr. Parada graduated from the University of Porto, Portugal and has a MBA from the Portuguese Catholic University. - Ant ó nio Parada于2024年11月被任命为iBio，Inc.董事会成员，目前担任提名和公司治理委员会成员。他目前是Fairjney Biologics的创始人兼首席执行官，该公司是一家私营公司，也是一家领先的抗体发现合同研究组织，为全球250多个客户提供支持，自2012年5月创立该公司以来，他一直担任这一职务。2024年6月，管理着约1500亿美元资产的全球私人市场最大公司之一Partners Group收购了FairJney的多数股权。在加入Fairjney之前，Parada先生曾于2002年至2013年担任葡萄牙Porta的Instituto de Biologia Molecular e Celular（IBMC）总经理。从2011年2月至2012年5月，Parada先生担任IPO Porto –葡萄牙波尔图肿瘤医院临床试验部门的经理。从2008年6月到2012年3月，Parada先生是Ablynx’（赛诺菲 S.A.的子公司）位于葡萄牙Portal的“噬菌体显示卓越中心”的现场经理。2002年6月，帕拉达先生创立了咨询公司BioCodex Group，并担任首席执行官直到2008年12月，该公司的营业额约为1000万欧元。Parada先生于2014年5月至2017年5月期间担任Centro de Diagn ó stico y Estudios Metab ó licos Avanzados de Cantabria（CDEMAC）的董事会成员，现任EMBLEM监事会主席，自2011年1月起担任该职务。帕拉达先生有15篇关于药理学的同行复刊jnals和其他几篇关于植物学、管理、营销和安全的出版物，并持有葡萄牙波尔图市的功绩勋章和葡萄牙马托西尼奥斯市的事业奖。Parada先生毕业于葡萄牙波尔图大学，拥有葡萄牙天主教大学MBA学位。
- António Parada was appointed as a member of iBio, Inc. Board of Directors in November 2024 and currently serves as a member of the Nominating and Corporate Governance Committee. He is currently the Founder and CEO of Fairjney Biologics, a privately held company and a leading antibody discovery contract research organization supporting more than 250 clients across the globe, a role he has held since founding the company in May 2012. In June 2024, the Partners Group, one of the largest firms in the global private markets indtry with approximately $150 billion in assets under management, acquired a majority ownership in FairJney. Prior to Fairjney, Mr. Parada was the General Manager of Instituto de Biologia Molecular e Celular (IBMC), in Porta, Portugal, from 2002 until 2013. From February 2011 until May 2012, Mr. Parada was the Manager of the Clinical Trial Unit of IPO Porto – Cancer Hospital in Porto, Portugal. From June 2008 to March 2012, Mr. Parada was the Site Manager of Ablynx' (a subsidiary of Sanofi S.A.) "Centre of Excellence in Phage Display" located in Portal, Portugal. In June 2002, Mr. Parada founded the BioCodex Group, a consulting firm, and was the CEO until December 2008, which firm had a turnover of approximately 10 million Euros. Mr. Parada was a Board Member of Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 until May 2017 and is currently the Chairman of the Supervisory Board of EMBLEM, a position he has held since January 2011. Mr. Parada has 15 publications in peer revied jnals on pharmacology and several others in botany, management, marketing and security and holds the medal of Merit of the city of Porto, Portugal and career award of the city of Matosinhos, Portugal. Mr. Parada graduated from the University of Porto, Portugal and has a MBA from the Portuguese Catholic University.
高管简历
中英对照 | 中文 | 英文- Martin B. Brenner
MartinB.Brenner自2019年3月起担任我们的高级副总裁，首席科学官。2017年至2018年，Brenner博士担任生物技术公司Recursion Pharmaceuticals，Inc.的首席科学官。2016年至2017年，Brenner博士担任生物技术公司StokeTherapeutics，Inc.的Vice President兼研发主管。从2013年到2016年，Brenner博士担任默克制药公司默克研究实验室（Merck Research Laboratories）糖尿病与NASH执行董事兼糖尿病与NASH早期发现部门主席。2012年至2013年，Brenner博士担任制药公司AstraZeneca PLC CVMD的高级董事、生物科学主管。从2009年到2012年，Brenner博士担任制药公司辉瑞公司糖尿病预防和缓解组的副研究员。从2003年到2009年，Brenner博士担任礼来公司（一家制药公司）糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威的汉诺威兽医学院（Veterinary School of Hannover）药理学博士学位和德国慕尼黑的路德维希-马克西米利安大学（Ludwig-Maximilians-University）兽医学院的DVM。
Martin B. Brenner,has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.- MartinB.Brenner自2019年3月起担任我们的高级副总裁，首席科学官。2017年至2018年，Brenner博士担任生物技术公司Recursion Pharmaceuticals，Inc.的首席科学官。2016年至2017年，Brenner博士担任生物技术公司StokeTherapeutics，Inc.的Vice President兼研发主管。从2013年到2016年，Brenner博士担任默克制药公司默克研究实验室（Merck Research Laboratories）糖尿病与NASH执行董事兼糖尿病与NASH早期发现部门主席。2012年至2013年，Brenner博士担任制药公司AstraZeneca PLC CVMD的高级董事、生物科学主管。从2009年到2012年，Brenner博士担任制药公司辉瑞公司糖尿病预防和缓解组的副研究员。从2003年到2009年，Brenner博士担任礼来公司（一家制药公司）糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威的汉诺威兽医学院（Veterinary School of Hannover）药理学博士学位和德国慕尼黑的路德维希-马克西米利安大学（Ludwig-Maximilians-University）兽医学院的DVM。
- Martin B. Brenner,has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.
- Felipe Duran
Felipe Duran，自2023年6月起担任iBio, Inc.首席财务官（CFO）。杜兰先生于2021年4月至2023年2月担任iBio的财务规划和分析副总裁（“FP & A”），并于2023年2月至2023年6月担任公司临时首席财务官。此前，Duran先生于2016年5月至2021年5月担任Lupin Latin America的执行董事（CFO），Lupin Latin America是美国第三大仿制药公司Lupin Pharmaceuticals的子公司。在加入Lupin Pharmaceuticals之前，他曾在Teva Pharmaceuticals的成长型市场和拉丁美洲办事处担任多个战略职位。杜兰先生还曾在保柏和诺文制药担任FP & A经理。杜兰拥有迈阿密大学金融学学士和工商管理硕士学位。
Felipe Duran has been iBio's Chief Financial Officer (CFO) since June 2023 and prior thereto from January 20, 2023 he served as iBio's interim CFO, and previoly as iBio's Vice President of Financial Planning and Analysis (FP&A) from May 2021. Previoly, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, overseeing finance, IT and supply chain for the region and for the R&D finance organization, from May 2016 to May 2021. Previoly, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, from May 2016 – May 2021. In this role, Mr. Duran was responsible for finance, IT and supply chain for Latin America. Additionally, Mr. Duran was responsible for the R&D finance organization. Prior to joining Lupin Pharmaceuticals, Mr. Duran held vario strategic positions at Teva Pharmaceuticals in both its growth markets and Latin America regions. Earlier in his career, Mr. Duran held FP&A and other financial related roles with British United Provident Association Limited (BUPA), a multi national health insurance and healthcare company, Noven Pharmaceuticals, Inc., Bayview Asset Management, LLC., HIG Capital and IBM Corporation. Mr. Duran received a B.A. in Finance and an M.B.A from the University of Miami.- Felipe Duran，自2023年6月起担任iBio, Inc.首席财务官（CFO）。杜兰先生于2021年4月至2023年2月担任iBio的财务规划和分析副总裁（“FP & A”），并于2023年2月至2023年6月担任公司临时首席财务官。此前，Duran先生于2016年5月至2021年5月担任Lupin Latin America的执行董事（CFO），Lupin Latin America是美国第三大仿制药公司Lupin Pharmaceuticals的子公司。在加入Lupin Pharmaceuticals之前，他曾在Teva Pharmaceuticals的成长型市场和拉丁美洲办事处担任多个战略职位。杜兰先生还曾在保柏和诺文制药担任FP & A经理。杜兰拥有迈阿密大学金融学学士和工商管理硕士学位。
- Felipe Duran has been iBio's Chief Financial Officer (CFO) since June 2023 and prior thereto from January 20, 2023 he served as iBio's interim CFO, and previoly as iBio's Vice President of Financial Planning and Analysis (FP&A) from May 2021. Previoly, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, overseeing finance, IT and supply chain for the region and for the R&D finance organization, from May 2016 to May 2021. Previoly, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, from May 2016 – May 2021. In this role, Mr. Duran was responsible for finance, IT and supply chain for Latin America. Additionally, Mr. Duran was responsible for the R&D finance organization. Prior to joining Lupin Pharmaceuticals, Mr. Duran held vario strategic positions at Teva Pharmaceuticals in both its growth markets and Latin America regions. Earlier in his career, Mr. Duran held FP&A and other financial related roles with British United Provident Association Limited (BUPA), a multi national health insurance and healthcare company, Noven Pharmaceuticals, Inc., Bayview Asset Management, LLC., HIG Capital and IBM Corporation. Mr. Duran received a B.A. in Finance and an M.B.A from the University of Miami.
- Marc Banjak
Marc Banjak自2024年8月起担任iBio的首席法务官（CLO），在此之前自2022年2月21日起担任iBio的总法律顾问和公司秘书。Banjak先生此前曾担任私营公司Istari Oncology和当时的上市公司Dova制药的首任总法律顾问，领导这两个组织内的法律和合规职能。在Dova任职期间，Banjak先生通过瑞典Orphan Biovitrum AB收购Dova为公司提供咨询服务。在此之前，Banjak先生曾在PRA健康科学、B.博朗医疗、PPD担任律师。在进入生物技术和合同研究行业之前，班贾克曾在美国空军担任现役军官，担任过各种法律职务。班贾克先生被科罗拉多州律师协会录取。Banjak先生在丹佛大学法学院获得了京东学位，并在富兰克林和马歇尔学院获得了心理学学士学位。
Marc Banjak,has been iBio's Chief Legal Officer (CLO) since August 2024 and prior thereto from February 21, 2022 he served as iBio's General Counsel and Corporate Secretary. Mr. Banjak previously served as the first general counsel of both Istari Oncology, a privately-held company, and Dova Pharmaceuticals, then a publicly traded company, leading the legal and compliance functions within both organizations. While at Dova, Mr. Banjak advised the company through the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak worked as an attorney at PRA Health Sciences, B. Braun Medical, and PPD. Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active-duty officer in the U.S. Air Force in a variety of legal roles. Mr. Banjak is admitted to the Colorado state bar. Mr. Banjak earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College.- Marc Banjak自2024年8月起担任iBio的首席法务官（CLO），在此之前自2022年2月21日起担任iBio的总法律顾问和公司秘书。Banjak先生此前曾担任私营公司Istari Oncology和当时的上市公司Dova制药的首任总法律顾问，领导这两个组织内的法律和合规职能。在Dova任职期间，Banjak先生通过瑞典Orphan Biovitrum AB收购Dova为公司提供咨询服务。在此之前，Banjak先生曾在PRA健康科学、B.博朗医疗、PPD担任律师。在进入生物技术和合同研究行业之前，班贾克曾在美国空军担任现役军官，担任过各种法律职务。班贾克先生被科罗拉多州律师协会录取。Banjak先生在丹佛大学法学院获得了京东学位，并在富兰克林和马歇尔学院获得了心理学学士学位。
- Marc Banjak,has been iBio's Chief Legal Officer (CLO) since August 2024 and prior thereto from February 21, 2022 he served as iBio's General Counsel and Corporate Secretary. Mr. Banjak previously served as the first general counsel of both Istari Oncology, a privately-held company, and Dova Pharmaceuticals, then a publicly traded company, leading the legal and compliance functions within both organizations. While at Dova, Mr. Banjak advised the company through the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak worked as an attorney at PRA Health Sciences, B. Braun Medical, and PPD. Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active-duty officer in the U.S. Air Force in a variety of legal roles. Mr. Banjak is admitted to the Colorado state bar. Mr. Banjak earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College.